In particular, gefitinib and the anti-IL10 antibodies were individually effective at reducing the amount of tumor cells, and the combination of gefitinib with the anti-IL10 antibody further inhibited lung cancer formation (Figure 4E), suggesting that neutralizing IL10 synergistically blocks lung cancer malignancy through EGFR inhibition. Here, IL10 is linked to neoplasm.